低风险疫苗接种临床试验参与者对基于小组的在线知情同意对话(eConsent)的评价
SWITCH-ON研究成功招募434名18-65岁医护人员,向其发放关于小组在线知情同意体验的问卷,399份完成问卷中360份纳入分析。参与者认为小组eConsent高效、能互相听到疑问并营造共同感,但隐私受限、小组中提问障碍和同伴压力限制其使用;参与者建议以网络研讨会提供一般信息后为每人安排单独会话。
要点
- 小组eConsent被低风险疫苗试验参与者积极评价,但隐私受限与同伴压力是主要限制
- 165名(46%)参与者认为小组eConsent适合招募患有疾病或健康状况的参与者
- 参与者建议先以网络研讨会提供研究一般信息,再为每位参与者安排单独会话
核心结论
- 小组eConsent在低风险疫苗接种研究的参与者中获得积极评价。
- 参与者建议使用网络研讨会提供研究的一般信息,随后为每位参与者安排单独会话,以保留小组eConsent的优点并减少其带来的限制。
研究设计与样本
- SWITCH-ON研究旨在分析健康人群接种二价COVID-19加强疫苗后的免疫原性。
- 成功招募434名18-65岁医护人员并发送关于小组eConsent体验的问卷,399份完成问卷(应答率92%),其中39人未参加小组eConsent,其余360份回答纳入最终分析。
- 定量与定性数据分别采用描述性统计分析和主题分析报告。
- 试验注册:ClinicalTrials.gov NCT05471440,注册日期2022年7月22日。
主要发现
- 参与者认为小组eConsent是一种高效的方法,使其能够听到彼此的疑问和关切并营造出共同感。
- 隐私受限、在小组中提问的障碍以及同伴压力可能限制小组eConsent的使用。
- 165名(46%)参与者认为小组eConsent适合招募患有疾病或健康状况的参与者,87名(24%)报告该方法存在限制。
- 其余参与者提出小组eConsent的适用性取决于研究人群的疾病或健康状况,且应始终提供一对一对话。
- 既经历过一对一又经历过小组eConsent的参与者对未来研究偏好的知情同意形式各不相同。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Electronic informed consent (eConsent) usage has expanded in recent years in Europe, especially during the pandemic. Slow recruitment rate and limitations in participant outreach are the challenges often faced in clinical research. Given the benefits of eConsent and group counselling reported in the literature, group eConsent was implemented in recruitment for the SWITCH-ON study. We aim to explore the experience of participants who attended group eConsent for the SWITCH-ON study and evaluate its potential for future use. METHODS: SWITCH-ON study aims to analyse the immunogenicity of a healthy population following bivalent COVID-19 booster vaccination. Four hundred thirty-four healthcare workers aged 18-65 were successfully recruited and sent a questionnaire about their experience with group eConsent. Out of 399 completed questionnaires (response rate 92%), 39 participants did not join group eConsent. The remaining 360 responses were included in the final analysis. Quantitative and qualitative data were reported using descriptive statistical analysis and thematic analysis respectively. RESULTS: Participants found that group eConsent was an efficient method that it allowed them to hear each other's questions and concerns and created a sense of togetherness. However, limited privacy, barriers to asking questions in a group, and peer pressure can limit the use of group eConsent. One hundred sixty-five (46%) participants thought that group eConsent was suitable to recruit participants with diseases or conditions, while 87 (24%) reported limitations with this method. The remaining participants suggested that applicability of group eConsent depended on the diseases or conditions of the study population, and one-to-one conversation should always be available. Participants who had experienced both one-to-one and group eConsent shared different preferred consent formats for future studies. CONCLUSION: Group eConsent was positively evaluated by the participants of a low-risk vaccination study. Participants advised using webinars to provide general information about the study, followed by an individual session for each participant, would retain the benefits of group eConsent and minimise the limitations it posed. This proposed setting addresses privacy questions and makes group eConsent easier to implement. TRIAL REGISTRATION: ClinicalTrials.gov NCT05471440 (registered on 22nd of July, 2022).
引用
- Tan NH, Lafeber M, Sablerolles RSG, et al. Evaluation of a group-based online informed consent conversation (eConsent) in participants from a low-risk vaccination clinical trial. Trials. 2024. PMID: 39107860. doi:10.1186/s13063-024-08367-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。